PAR 1.92% 25.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-4121

  1. 4,170 Posts.
    lightbulb Created with Sketch. 6642
    Nah..we have covered it over a few iterations in the past...

    V high level summary:

    - Expensive
    - Hit and miss, can work wonders on a few, others are meh.
    - Individualised, hard to scale
    - None really approved by authorities, maybe a couple but very specific applications


    Might develop over time, our market is huge, there would be room for multiple players if Stem Cell area does improve and becomes cheaper/accessible/efficacious


    There is prob more scope in eventual combination therapy...ie iPPS and stem cell together.


    My thoughts, DYOR


 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
25.5¢
Change
-0.005(1.92%)
Mkt cap ! $89.19M
Open High Low Value Volume
27.0¢ 27.0¢ 25.5¢ $261.4K 990.7K

Buyers (Bids)

No. Vol. Price($)
1 9999 25.5¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 9445 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.